Targeted Genetics, the Seattle-based developer of gene therapies, said today that three of the six members of its board of directors have stepped down. They departures aren’t because of a boardroom disagreement, but are intended to help save costs, Targeted said in a statement. Joseph Davie, Roger Hawley, and Nelson Levy have left the board, while Jeremy Curnock Cook, Michael Perry, and CEO Susan Robinson are keeping their board seats. The company has also made layoffs, and de-listed from the NASDAQ as part of its efforts to save cash.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
